HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women
Aims : To compare the effects of 3 months ' tibolone treatment with the effects of placebo on sexual function ( in particular , vaginal blood flow , and sexual desire and arousability ) and climacteric symptoms in postmenopausal women . Methods : A r and omized , double-blind , cross-over study was conducted in 38 postmenopausal women who received tibolone 2.5 mg/day and placebo .  Vaginal blood flow during erotic stimulation by fantasy and film was measured using a vaginal photoplethysmograph and subjects completed sexual function question naires and daily diaries . Results : Tibolone significantly increased baseline vaginal pulse amplitude ( VPA ) levels compared with placebo . There were significant treatment differences in VPA in favor of tibolone during fantasy periods but not during erotic film stimulation . Tibolone was associated with significant increases in sexual desire , and the frequency of arousability and of sexual fantasies compared with those with placebo .  Vaginal lubrication was significantly improved on tibolone . Twenty-five of 38 ( 66 % ) subjects correctly guessed when they were on active treatment . Tibolone was well tolerated . Conclusions : Tibolone was associated with significant improvements in sexual function  in postmenopausal women , reflecting both its estrogenic and and rogenic properties . There were significantly greater increases in vaginal blood flow with tibolone in response to erotic fantasy but not film , suggesting two possible pathways of female sexual response
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .